Tag Archives: 652 nm

ML7710 for photoactivated treatment of lung cancer

Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable patients to stay less time recovering at the hospital. It can also be repeated if needed multiple times without cumulating toxicities, unlike radiation therapy. Some previously inoperable tumors can decrease Continue reading →Deadliest cancer Lung cancer is the leading cause of cancer deaths worldwide, with more than 2.2 million cases and 1.8 million deaths each year [1]. Lung cancer can be divided into two types, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with the latter accounting for about 85% of all lung cancer cases. NSCL is usually less sensitive to chemo- and radiotherapy and in many cases tumor cannot be removed surgically or has spread from lungs to distant sites at the time Continue reading →

Light-based enhancement of vaccination in humans

  Motivation Vaccines should activate all branches of immunity, including T cells and antibody responses, for generating a strong immune response. For therapeutic cancer vaccines, it is especially important to induce strong cytotoxic T-cell responses, since cytotoxic T-cells are the most potent immune cells for killing cancer cells. While cytotoxic T-cells can often be induced  with viral vector and nucleic acid-based vaccines, peptide-based vaccines often induce only weak cytotoxic T-cell responses . When peptide antigens are taken up into antigen presenting cells, they are generally Continue reading →Customer case PCI Biotech is a biopharmaceutical company located in Norway. They are developing a novel light-based technology called photochemical internalization (PCI) that has potential to enhance delivery and efficacy of many types of therapies, including certain chemotherapies, peptide vaccines, and nucleic acid therapies. It can also decrease side effects due to improved spatiotemporal control of the treatment. The technology is currently in a pivotal clinical study for the treatment of inoperable bile duct cancer where PCI with gemcitabine is combined with standard gemcitabine/cisplatin chemotherapy. Continue reading →